In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival. This is according to a study in the June 18 issue of iJAMA/i. The modest improvement in clinical outcomes was accompanied by a high rate of adverse events. Uveal melanoma arises from melanocytes within the choroid ...
Read More
No comments:
Post a Comment